Evoke Pharma (EVOK) has agreed to be acquired by QOL Medical, LLC via a definitive Agreement and Plan of Merger structured as a two-step all-cash tender offer. The offer price is $11.00 per share, representing a 139.7% premium to the prior closing price. QOL affirms sufficient funds are available, and the transaction is expected to close by the end of 2025, focusing on integrating Evoke’s product, GIMOTI®, into QOL’s GI portfolio. Note that GIMOTI carries a Black Box Warning regarding Tardive Dyskinesia.
The Evoke Board unanimously recommends stockholders tender their shares. The
...